The Addiction Health Services Research (AHSR) Conference 2015:
Navigating a Changing Healthcare Landscape

is sponsored by

UCLA Integrated Substance Abuse Programs

The UCLA Integrated Substance Abuse Programs (ISAP) coordinates substance abuse research and treatment within the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.  As one of the largest substance abuse research groups in the United States, ISAP works to develop and evaluate new approaches for the treatment of substance abuse disorders; move empirically supported treatments into mainstream application; advance the empirical understanding of substance abuse and support efforts to ameliorate related problems; and investigate the epidemiology, neurobiology, consequences, treatment, and prevention of substance abuse.

With about 100 researchers, clinicians, and support personnel, ISAP is led by co-directors Richard A. Rawson, Ph.D., and Christine E. Grella, Ph.D.  ISAP’s network of activities includes pharmacological and behavioral clinical research, community-based research, research on public health policy, and substance abuse treatment services and training.  For more information, visit www.uclaisap.org

Pacific Southwest Addiction Technology Transfer Center
(Pacific Southwest ATTC)

Funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) as one of 10 regional centers and four national focus areas, the Pacific Southwest Addiction Technology Transfer Center (DHHS Region 9; Pacific Southwest ATTC) is jointly operated by UCLA Integrated Substance Abuse Programs, Arizona State University Center for Applied Behavioral Health Policy, and University of Nevada, Reno, Center for the Application of Substance Abuse Technologies. The Pacific Southwest ATTC’s vision is that all individuals with substance use disorders and related problems receive the most up-to-date, clinically effective, and culturally competent treatments to help them overcome their addiction, and, as a result, lead productive and meaningful lives.  The Pacific Southwest ATTC’s mission is to establish an infrastructure among key stakeholders in Arizona, California, Hawaii, Nevada, American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Palau, and Republic of the Marshall Islands to facilitate the transfer of addiction technology based on sound science through knowledge dissemination, training, and enhanced professional standards and practices that will improve the delivery of effective treatment for substance use disorders. Guiding principles include: collaboration, sound science, inclusion, information sharing, quality standards and programs, cultural competency, and informing public policy. For more information, visit www.psattc.org.




Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. In 1994, RB established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. The buprenorphine Business Group focused on developing buprenorphine for the treatment of opioid dependence. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we’ve partnered with and educated governments, policy makers, payers, and heathcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We’ve also worked diligently and strategically to identify and address the unmet treatment needs of patients. By creating a marketplace environment of increased acceptance, we have provided an estimated 5 million patients effective treatment options with SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII), and SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in the US alone, always keeping our focus on the individual. For more information, visit http://indivior.com/.


Tarzana Treatment Centers

Tarzana Treatment Centers

Tarzana Treatment Centers, Inc. (TTC) provides integrated care for substance use (alcohol and drugs), mental health, primary medical care, and HIV/AIDS services in ten locations in Los Angeles County. Since its founding in 1972, TTC has emerged as a cutting-edge provider in the field of integrated behavioral health care. Using innovation and a long-term vision, TTC has combined typical alcohol and drug treatment services with medical care, mental health, housing, case management and HIV/AIDS services to form an integrated delivery system that has set the standard that other organizations emulate.

Throughout its history, TTC has maintained focus on two primary goals: improving the quality of care provided to patients and expanding the number of patients who receive that care. Pursuit of these goals requires consistent attention to effectiveness of patient care combined with removal of barriers to accessing services, broadening of services to enable comprehensive care, and providing staff with the infrastructure needed to provide excellent care.

These aims require a commitment to leadership, patient advocacy, and innovation. The result of focus on these priorities has made TTC one of California’s largest providers of Integrated Behavioral Healthcare.